Advice
Not recommended for use within NHS Scotland.
RECOMMENDATION
Frovatriptan is another new 5-HT1 agonist, which is less effective at producing rapid relief of migraine, as measured at two hours, when compared with the most commonly prescribed 5- HT1 agonist. It is less expensive than other drugs in the class. However, the company provided no suitable analysis to demonstrate cost effectiveness of their product.
The licence holder has indicated their decision to resubmit.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Frovatriptan (Migard)
- SMC ID:
- 49/03
- Indication:
- Headache phase of migraine attacks with or without aura
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 04 July 2003